Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab +/- GM-CSF in mCRPC
NCT01530984Phase 2Withdrawn
- Start
- Jun 2015
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in metastatic castration-resistant prostate cancer (mCRPC). Planned start Jun 2015; status: withdrawn.
02
Drugs
ipilimumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01530984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01530984.